Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

Completed · Phase 2

Conditions studied: Hodgkin's Disease

In brief

The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with recurrent or resistant Hodgkin's disease (HD) treated with sequential administration of oral 6-Thioguanin (6-TG) after IV Methotrexate (MTX).

Key facts

Study ID

NCT00587873

Run by

Memorial Sloan Kettering Cancer Center

People needed

18

Starts

1994-03-01

Expected to finish

2009-06-01

Last updated by the study team

2009-06-12

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologic proof of HD who are in relapse and have failed > or = to 2 prior chemotherapy regimens.
• Patients must have a life expectancy of at least 8 weeks.
• All patients must have ECOG performance level rating of < or = to 2.
• Patients or their parents (guardian) must sign an informed consent indicating that they are aware of the investigational nature of the study.
• Patients must have recovered from the toxic effects of prior therapy before entering this study or at least 2 weeks should have elapsed since the end of last course of CT.
• Patients must have adequate liver function (bilirubin < or = to 2.0 mg/dl, SGOT less than 1.5 times normal (unless it is due to disease), adequate renal function (creatinine < or = to 1.5 mg/dl, creatinine clearance > or = to 60 ml/min/1.73 m2).
• Patients should have a granulocyte count > or = to 500/gL and a platelet count > or = to 100,000/uL (unless due to disease involvement of the bone marrow).
• Male and female patients of child-bearing age should use effective methods of contraception, if sexually active.

You may not qualify if…

• Patients with active infections or significant medical conditions other than their malignancy shall be excluded.
• Patients with HD who had prior MTX or 6-TG should be excluded.

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.